ATE129160T1 - Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. - Google Patents

Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.

Info

Publication number: ATE129160T1
Authority: AT; Austria
Prior art keywords: herpes simplex; monophosphoryl lipid; vaccine containing; hsv glycoprotein; containing hsv
Prior art date: 1991-03-21

Application number

AT92906441T

Other languages

English (en)

Inventor

Myriam Francotte

Jean-Paul Prieels

Moncef Slaoui

Nathalie Marie- Garcon-Johnson

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-21

Filing date

1992-03-17

Publication date

1995-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE129160(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-17 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1995-11-15 Application granted granted Critical

1995-11-15 Publication of ATE129160T1 publication Critical patent/ATE129160T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT92906441T 1991-03-21 1992-03-17 Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. ATE129160T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9105992A GB9105992D0 (en)	1991-03-21	1991-03-21	Vaccine

Publications (1)

Publication Number	Publication Date
ATE129160T1 true ATE129160T1 (de)	1995-11-15

Family

ID=10691946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92906441T ATE129160T1 (de)	1991-03-21	1992-03-17	Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.

Country Status (34)

Country	Link
US (1)	US6027730A (de)
EP (1)	EP0576478B2 (de)
JP (1)	JP3530526B2 (de)
KR (1)	KR100224329B1 (de)
CN (2)	CN1058191C (de)
AP (1)	AP298A (de)
AT (1)	ATE129160T1 (de)
AU (1)	AU650521B2 (de)
BR (1)	BR9205745A (de)
CA (1)	CA2106492C (de)
CY (1)	CY1936A (de)
CZ (1)	CZ280505B6 (de)
DE (1)	DE69205566T3 (de)
DK (1)	DK0576478T4 (de)
ES (1)	ES2081102T5 (de)
FI (1)	FI107881B (de)
GB (1)	GB9105992D0 (de)
GR (1)	GR3017884T3 (de)
HK (1)	HK1004525A1 (de)
HU (1)	HU218025B (de)
IE (1)	IE69560B1 (de)
IL (1)	IL101290A (de)
MA (1)	MA22471A1 (de)
MX (1)	MX9201245A (de)
MY (1)	MY110086A (de)
NO (1)	NO307499B1 (de)
NZ (1)	NZ242057A (de)
PL (1)	PL170059B1 (de)
PT (1)	PT100262B (de)
SA (1)	SA92120459B1 (de)
SK (1)	SK279190B6 (de)
WO (1)	WO1992016231A1 (de)
YU (1)	YU28392A (de)
ZA (1)	ZA922011B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) *	1992-02-12	1992-03-25	Smithkline Beecham Biolog	Vaccines
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (de) *	1993-02-19	1995-12-06	Smithkline Beecham Corporation	3-0-deacylierte monophoshoryl lipid a enthaltende influenzaimpfstoffzusammensetzungen
DE69405551T3 (de) *	1993-03-23	2005-10-20	Smithkline Beecham Biologicals S.A.	3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
CA2163550A1 (en) *	1993-05-25	1994-12-08	Gerald E. Hancock	Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
ES2196098T3 (es) *	1994-12-28	2003-12-16	Univ Kentucky Res Found	Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6949244B1 (en)	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en)	1996-04-12	2001-05-22	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en)	1996-04-12	2002-04-11	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en)	1996-12-05	2002-10-22	Quadrant Healthcare (Uk) Limited	Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en)	1997-06-13	2001-08-14	Malaya Chatterjee	Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en)	1997-11-17	2002-03-12	University Of Kentucky Research Foundation	Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) *	1998-09-11	1998-11-04	Smithkline Beecham Plc	New vaccine and method of use
US6692752B1 (en) *	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
DK1126876T3 (da)	1998-10-16	2007-07-02	Glaxosmithkline Biolog Sa	Adjuvanssystemer og vacciner
US7026155B2 (en)	1999-02-02	2006-04-11	Regents Of The University Of California	Method of reducing bacterial proliferation
EP1104767A1 (de)	1999-11-30	2001-06-06	Stichting Dienst Landbouwkundig Onderzoek	Mono- und Disaccharidederivate die sowohl Fettsäureestern als Sulfatestern enthalten
US9273326B2 (en)	2004-04-30	2016-03-01	The Brigham And Women's Hospital, Inc.	Tetracycline-regulated gene expression in HSV-1 vectors
JP2008513406A (ja)	2004-09-22	2008-05-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
WO2006100111A1 (en)	2005-03-23	2006-09-28	Glaxosmithkline Biologicals S.A.	Composition
EA014107B1 (ru)	2005-12-22	2010-10-29	Глаксосмитклайн Байолоджикалс С.А.	Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
US20100021503A1 (en)	2006-03-30	2010-01-28	Glaxosmithkline Biologicals S.A.	Immunogenic composition
MX2009000660A (es)	2006-07-17	2009-04-08	Glaxosmithkline Biolog Sa	Vacuna de influenza.
PL2484375T3 (pl)	2006-09-26	2018-09-28	Infectious Disease Research Institute	Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
PT2167121E (pt)	2007-06-26	2015-12-02	Glaxosmithkline Biolog Sa	Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
CA2797937C (en)	2009-05-22	2020-01-14	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2010256461B2 (en)	2009-06-05	2016-03-17	Access To Advanced Health Institute	Synthetic glucopyranosyl lipid adjuvants
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
EP2516629B1 (de) *	2009-12-21	2016-04-13	The Brigham and Women's Hospital, Inc.	Impfstoffe gegen den herpes-simplex-virus
CA2856697A1 (en)	2010-11-24	2012-06-07	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN103619350A (zh) *	2011-03-11	2014-03-05	麦克马斯特大学	包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
JP6054942B2 (ja)	2011-04-08	2016-12-27	イミューンデザインコーポレイション	免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
US10206996B2 (en)	2011-08-22	2019-02-19	Nanobio Corporation	Herpes simplex virus nanoemulsion vaccine
US9624273B2 (en)	2011-11-23	2017-04-18	Genocea Biosciences, Inc.	Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
SMT201800368T1 (it)	2012-05-16	2018-09-13	Immune Design Corp	Vaccini per l'infezione da virus-2 herpes simplex
CA2897398A1 (en)	2013-01-07	2014-07-10	Biomedical Research Models, Inc.	Use of vaccines for the treatment of herpes simplex virus type 2 infections
WO2014172637A1 (en)	2013-04-18	2014-10-23	Immune Design Corp.	Gla monotherapy for use in cancer treatment
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
JP2019537555A (ja)	2016-09-28	2019-12-26	ジェノセアバイオサイエンシーズ，インコーポレイテッド	ヘルペスを処置するための方法および組成物
US11390650B2 (en)	2018-02-05	2022-07-19	The Brigham And Women's Hospital, Inc.	Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
EP4277654A1 (de)	2021-01-18	2023-11-22	Conserv Bioscience Limited	Immunogene coronavirus-zusammensetzungen, verfahren und verwendungen davon

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4372945A (en) *	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en) *	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) *	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) *	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
US5149660A (en) *	1982-02-18	1992-09-22	University Patents, Inc.	Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) *	1983-08-30	1991-08-27	Genentech Inc	Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
DE3751772T2 (de) *	1986-10-20	1996-12-05	Chiron Corp	Impfstoff zur behandlung von hsv
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
NZ230424A (en) *	1988-08-25	1992-05-26	Liposome Co Inc	Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) *	1988-10-27	1999-10-04	リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ	Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) *	1989-05-04	1997-01-28	Igen, Inc.	Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) *	1989-07-21	1992-10-27	Wisconsin Alumni Research Foundation	Method of stimulating the immune systems of animals and compositions useful therefor
EP0482068A1 (de) *	1989-07-14	1992-04-29	American Cyanamid Company	Cytokin- und hormonträger zur verwendung bei konjugatimpfstoffen
WO1992002252A1 (en) *	1990-08-01	1992-02-20	Research Corporation Technologies, Inc.	The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
ES2134197T3 (es) *	1990-08-02	1999-10-01	Chiron Corp	Vacunas contra el virus del herpes simplex vp16.
GB9106048D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccines
US5166173A (en) *	1991-01-29	1992-11-24	Genelabs Incorporated	Method of treating herpes simplex virus infection
US5196452A (en) *	1991-01-29	1993-03-23	Genelabs Incorporated	Macrocyclic anti-viral compound and method
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
DK0761231T3 (da) *	1992-06-25	2000-05-08	Smithkline Beecham Biolog	Vaccinepræparat indeholdende adjuvanser
EP0684838A1 (de) *	1993-02-19	1995-12-06	Smithkline Beecham Corporation	3-0-deacylierte monophoshoryl lipid a enthaltende influenzaimpfstoffzusammensetzungen
DE69405551T3 (de) *	1993-03-23	2005-10-20	Smithkline Beecham Biologicals S.A.	3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
CA2163550A1 (en) *	1993-05-25	1994-12-08	Gerald E. Hancock	Adjuvants for vaccines against respiratory syncytial virus

1991
- 1991-03-21 GB GB9105992A patent/GB9105992D0/en active Pending
1992
- 1992-03-17 CA CA 2106492 patent/CA2106492C/en not_active Expired - Lifetime
- 1992-03-17 JP JP50598492A patent/JP3530526B2/ja not_active Expired - Lifetime
- 1992-03-17 DK DK92906441T patent/DK0576478T4/da active
- 1992-03-17 DE DE69205566T patent/DE69205566T3/de not_active Expired - Lifetime
- 1992-03-17 PL PL92300617A patent/PL170059B1/pl unknown
- 1992-03-17 CZ CS931958A patent/CZ280505B6/cs not_active IP Right Cessation
- 1992-03-17 WO PCT/EP1992/000592 patent/WO1992016231A1/en active IP Right Grant
- 1992-03-17 EP EP19920906441 patent/EP0576478B2/de not_active Expired - Lifetime
- 1992-03-17 AT AT92906441T patent/ATE129160T1/de active
- 1992-03-17 BR BR9205745A patent/BR9205745A/pt not_active Application Discontinuation
- 1992-03-17 CY CY193692A patent/CY1936A/xx unknown
- 1992-03-17 AU AU13657/92A patent/AU650521B2/en not_active Expired
- 1992-03-17 SK SK946-93A patent/SK279190B6/sk unknown
- 1992-03-17 HU HU9302645A patent/HU218025B/hu unknown
- 1992-03-17 KR KR1019930702835A patent/KR100224329B1/ko not_active IP Right Cessation
- 1992-03-17 ES ES92906441T patent/ES2081102T5/es not_active Expired - Lifetime
- 1992-03-18 MY MYPI92000448A patent/MY110086A/en unknown
- 1992-03-19 IE IE920881A patent/IE69560B1/en not_active IP Right Cessation
- 1992-03-19 MA MA22760A patent/MA22471A1/fr unknown
- 1992-03-19 CN CN92102950A patent/CN1058191C/zh not_active Expired - Lifetime
- 1992-03-19 NZ NZ242057A patent/NZ242057A/en not_active IP Right Cessation
- 1992-03-19 PT PT100262A patent/PT100262B/pt not_active IP Right Cessation
- 1992-03-19 IL IL10129092A patent/IL101290A/en not_active IP Right Cessation
- 1992-03-19 ZA ZA922011A patent/ZA922011B/xx unknown
- 1992-03-20 AP APAP/P/1992/000368A patent/AP298A/en active
- 1992-03-20 MX MX9201245A patent/MX9201245A/es unknown
- 1992-03-20 YU YU28392A patent/YU28392A/sh unknown
- 1992-04-21 SA SA92120459A patent/SA92120459B1/ar unknown
1993
- 1993-09-20 NO NO933343A patent/NO307499B1/no not_active IP Right Cessation
- 1993-09-21 FI FI934134A patent/FI107881B/fi not_active IP Right Cessation
1994
- 1994-09-09 US US08/303,542 patent/US6027730A/en not_active Expired - Lifetime
1995
- 1995-10-25 GR GR950402992T patent/GR3017884T3/el unknown
1998
- 1998-01-05 CN CN98103933A patent/CN1101226C/zh not_active Expired - Lifetime
- 1998-04-28 HK HK98103623A patent/HK1004525A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK279190B6 (sk)	1998-07-08
MA22471A1 (fr)	1992-10-01
IL101290A0 (en)	1992-11-15
DE69205566D1 (en)	1995-11-23
ZA922011B (en)	1993-01-27
KR100224329B1 (ko)	1999-10-15
HU9302645D0 (en)	1994-01-28
GB9105992D0 (en)	1991-05-08
PT100262A (pt)	1993-06-30
EP0576478B2 (de)	2001-04-18
PT100262B (pt)	2001-05-31
FI934134L (fi)	1993-09-21
MX9201245A (es)	1992-10-01
HU218025B (hu)	2000-05-28
DE69205566T3 (de)	2002-09-05
CN1065997A (zh)	1992-11-11
AP298A (en)	1994-01-14
NO933343D0 (no)	1993-09-20
IL101290A (en)	1996-07-23
IE69560B1 (en)	1996-10-02
CN1201692A (zh)	1998-12-16
BR9205745A (pt)	1994-10-18
NZ242057A (en)	1993-12-23
HK1004525A1 (en)	1998-11-27
NO307499B1 (no)	2000-04-17
US6027730A (en)	2000-02-22
AU1365792A (en)	1992-10-21
CA2106492C (en)	2003-12-09
NO933343L (no)	1993-09-20
ES2081102T5 (es)	2001-09-01
EP0576478A1 (de)	1994-01-05
YU28392A (sh)	1994-11-15
PL170059B1 (pl)	1996-10-31
SA92120459B1 (ar)	2005-06-14
DK0576478T3 (da)	1995-12-04
AP9200368A0 (en)	1992-04-30
CA2106492A1 (en)	1992-09-22
FI107881B (fi)	2001-10-31
CY1936A (en)	1992-03-17
HUT67052A (en)	1995-01-30
DK0576478T4 (da)	2001-07-23
MY110086A (en)	1997-12-31
CZ280505B6 (cs)	1996-02-14
EP0576478B1 (de)	1995-10-18
AU650521B2 (en)	1994-06-23
CZ195893A3 (en)	1994-07-13
ES2081102T3 (es)	1996-02-16
DE69205566T2 (de)	1996-04-18
CN1101226C (zh)	2003-02-12
JPH06505727A (ja)	1994-06-30
CN1058191C (zh)	2000-11-08
IE920881A1 (en)	1992-09-23
WO1992016231A1 (en)	1992-10-01
JP3530526B2 (ja)	2004-05-24
GR3017884T3 (en)	1996-01-31
SK94693A3 (en)	1994-05-11
FI934134A0 (fi)	1993-09-21

Publication	Publication Date	Title
ATE129160T1 (de)	1995-11-15	Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.
CY2007016I1 (el)	2009-11-04	Εμβολιο ιου θηλωματος
DE3685847D1 (de)	1992-08-06	Infrarot projektoranordnung.
GB9106048D0 (en)	1991-05-08	Vaccines
OA08199A (en)	1987-10-30	Vaccine.
CY2008005I2 (el)	2018-01-10	Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn
EP0595970A4 (de)	1995-05-31	Verbesserter impfstoff.
EP0236487A4 (de)	1989-12-28	Virus-inaktivierung.
EP0266401A4 (de)	1988-09-28	Impfstoffe.
GB9125896D0 (en)	1992-02-05	Bicistronic viruses
GB8602707D0 (en)	1986-03-12	Non-linear optics
HU9203976D0 (en)	1993-03-29	Vaccine based on modified herpes virus
GB8602706D0 (en)	1986-03-12	Non-linear optics
GB8602708D0 (en)	1986-03-12	Non-linear optics
ZA939564B (en)	1994-08-15	Vaccines.
FI922855A0 (fi)	1992-06-18	Laett foerslutningsbar paose eller saeck.
GB9225535D0 (en)	1993-01-27	Bicistronic viruses
EP0681480A4 (de)	1997-06-25	Recognin vakzine.
FR2678672B1 (fr)	1995-11-03	Coffre-fort demontable.
ZA924670B (en)	1993-03-31	Ccv vaccine
IT8921185A0 (it)	1989-07-14	Mina.
EP0621893A4 (de)	1995-07-12	Impfstoffe gegen den leukämievirus der katze.
DE3768117D1 (de)	1991-04-04	Transportsicherung.
GB9305710D0 (en)	1993-05-05	Viral vaccines
GB9324964D0 (en)	1994-01-26	Viral vaccines

Legal Events

Date	Code	Title	Description
1996-05-15	UEP	Publication of translation of european patent specification
2001-09-15	UEP	Publication of translation of european patent specification